Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data
Researchers in Texas found that SRA737, when combined with immunotherapy and low dose gemcitabine, had a “dramatic enhancement” in anti-tumour activity
Company
Sareum Holdings PLC
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 5 of 12
Archive
Proactive news snapshot: Shanta Gold, Amryt Pharma, Greencoat UK Wind …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Block Energy, H&T Group, ClearStar …
A glance at some of the day's highlights from the Proactive Investors newswire
Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal
The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches
Archive
Proactive news snapshot: Sunrise Resources, Taptica International, Physiomics …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: ValiRx, Avation, Sativa Investments …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Urals Energy tumbles again as war of words with Sergey Kononov intensifies
A look at the day's major movers, including redT, Rockfire, Oilex, SPDI and Orosur Mining
Sareum Holdings chairman says drug discovery group is making progress
At the company’s annual meeting, being held in the City of London, chairman Dr Stephen Parker will point to the progress of SRA737, which has been licensed to Sierra Oncology
Archive
Indivior investor call to be among the key highlights for Tuesday
Addiction drug firm Indivior is updating investors in the wake of a recent decision by the US Court of Appeals.
Archive
Fed could be Grinch-like in final full trading week before Christmas, but BoE seen more festive
Aside from the UK and US rate decisions, the latest UK inflation and retail data will be closely eyed as well in the absence of almost anything on the corporate diary
Archive
Proactive news snapshot: Redx Pharma, Active Energy , Live Company …
A glance at some of the day's highlights from the Proactive Investors newswire
Webis weak on limited California license renewal; Kier Group drops on cash call
A look at some winners and losers in the UK equity market on Friday
Sareum’s SRA737 Chk1 inhibitor impresses once again
Sierra Oncology, the US firm which is licensing Sareum’s SRA737 compound, published more data overnight
FTSE 100 closes lower as G20 summit begins and trade worries continue; housebuilders fall
The premier index of UK shares finished down nearly 59 points at 6,980. Mid-cap cousin FTSE 250 shed over 128 points at 18,480.
Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer
Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer
Archive
Proactive news snapshot: VR Education, Bigdish, Learning Technologies …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Haydale Graphene Industries, Tissue Regenix, to Hurricane Energy …
A glance at some of the day's highlights from the Proactive Investors newswire